{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638065,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We conducted a comprehensive analysis of esketamine-related adverse events (AE) on the FDA Adverse Event Reporting System (FAERS) database, taking into account for the first time drug-drug interaction signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective case\/non-case study of esketamine-related AEs reported in the FAERS database up to the last quarter (Q4) of 2024. Potential signals were detected using the reporting odds ratio (ROR) and confidence intervals (CI), while drug-drug interactions were studied using different metrics such as lift, conviction and the combination risk ratio detection algorithm. An analysis of sex differences was also performed using the relative ROR and CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis of 7,790 reports in which esketamine was a primary or secondary suspect identified potential safety signals for 173 AEs. Novel signals include homicidal ideation (ROR = 5.30, 95% CI: 2.38-11.82) and substance use disorder (ROR = 6.12, 95% CI: 2.54-14.73). Women showed a longer time to onset than men (p = 0.003). In addition, we detected sex differences in 23 AEs, seven of which were more likely to be reported in women, while 16 in men. Among these, four were significant exclusively in women (oxygen saturation decreased, abnormal behaviour, unresponsive to stimuli and aggression) and two in men (vision blurred and bradycardia). Potential signals of additive and multiplicative drug-drug interactions were detected for antidepressants (venlafaxine for\u201cdizziness\u201d and bupropion for \u201cagitation\u201d) and antipsychotics (risperidone for \u201cvertigo\u201d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-025-03954-z","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:30:02Z","timestamp":1766385002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals"],"prefix":"10.1007","volume":"82","author":[{"given":"Claudia","family":"Pisanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"10161","key":"3954_CR1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ (2018) Depression. Lancet 392(10161):2299\u20132312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31948-2","journal-title":"Lancet"},{"key":"3954_CR2","volume-title":"The global burden of disease: 2004 update","author":"WHO","year":"2008","unstructured":"WHO (2008) The global burden of disease: 2004 update. World Health Organization. In: ed, Geneva"},{"key":"3954_CR3","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr., Stahl S (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 178(5):383\u2013399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251","DOI":"10.1176\/appi.ajp.2020.20081251"},{"issue":"12","key":"3954_CR4","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1111\/bcp.15467","volume":"88","author":"IM Langmia","year":"2022","unstructured":"Langmia IM, Just KS, Yamoune S, Muller JP, Stingl JC (2022) Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective. Br J Clin Pharmacol 88(12):5149\u20135165. https:\/\/doi.org\/10.1111\/bcp.15467","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3954_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol 35(2):109\u2013123. https:\/\/doi.org\/10.1177\/0269881120959644","journal-title":"J Psychopharmacol"},{"issue":"2","key":"3954_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S (2013) WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf 36(2):75\u201381. https:\/\/doi.org\/10.1007\/s40264-012-0014-6","journal-title":"Drug Saf"},{"issue":"1","key":"3954_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G (2021) Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother Psychosom 90(1):41\u201348. https:\/\/doi.org\/10.1159\/000510703","journal-title":"Psychother Psychosom"},{"key":"3954_CR8","doi-asserted-by":"publisher","first-page":"849758","DOI":"10.3389\/fphar.2022.849758","volume":"13","author":"H Guo","year":"2022","unstructured":"Guo H, Wang B, Yuan S, Wu S, Liu J, He M, Wang J (2022) Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front Pharmacol 13:849758. https:\/\/doi.org\/10.3389\/fphar.2022.849758","journal-title":"Front Pharmacol"},{"key":"3954_CR9","doi-asserted-by":"publisher","first-page":"1414703","DOI":"10.3389\/fphar.2024.1414703","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu R, Liu C, Feng D, Guo T, Wang Y (2024) Pharmacovigilance of Esketamine nasal spray: an analysis of the FDA adverse event reporting system database. Front Pharmacol 15:1414703. https:\/\/doi.org\/10.3389\/fphar.2024.1414703","journal-title":"Front Pharmacol"},{"key":"3954_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jad.2024.07.128","volume":"363","author":"ATH Kwan","year":"2024","unstructured":"Kwan ATH, Rosenblat JD, Mansur RB, Rhee TG, Teopiz K, Le GH, Wong S, Cao B, Ho R, McIntyre RS (2024) A replication study using the world health organization pharmacovigilance database (VigiBase(R)) to evaluate whether an association between ketamine and Esketamine and alcohol and substance misuse exists. J Affect Disord 363:589\u2013594. https:\/\/doi.org\/10.1016\/j.jad.2024.07.128","journal-title":"J Affect Disord"},{"key":"3954_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jad.2024.05.116","volume":"360","author":"ATH Kwan","year":"2024","unstructured":"Kwan ATH, Rosenblat JD, Mansur RB, Teopiz KM, McIntyre RS (2024) The association between ketamine and Esketamine with alcohol and substance misuse: reports to the food and drug administration adverse event reporting system (FAERS). J Affect Disord 360:421\u2013426. https:\/\/doi.org\/10.1016\/j.jad.2024.05.116","journal-title":"J Affect Disord"},{"key":"3954_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H (2023) The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-023-01732-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3954_CR13","doi-asserted-by":"publisher","first-page":"1329436","DOI":"10.3389\/fphar.2024.1329436","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Chen D (2024) Comparing the adverse effects of ketamine and Esketamine between genders using FAERS data. Front Pharmacol 15:1329436. https:\/\/doi.org\/10.3389\/fphar.2024.1329436","journal-title":"Front Pharmacol"},{"key":"3954_CR14","unstructured":"Spravato Summary of Product Characteristics. In: ed"},{"key":"3954_CR15","unstructured":"MedDRA Medical Dictionary for Regulatory Activities (MedDRA),. In: ed"},{"issue":"8","key":"3954_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/cid\/ciac128","volume":"75","author":"M Chuma","year":"2022","unstructured":"Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y, Ishizawa K (2022) Association between Statin use and Daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis. Clin Infect Dis 75(8):1416\u20131422. https:\/\/doi.org\/10.1093\/cid\/ciac128","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3954_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","volume":"44","author":"C Wei","year":"2022","unstructured":"Wei C, Liu Y, Jiang A, Wu B (2022) A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on food and drug administration adverse event reporting system data. Int J Clin Pharm 44(3):709\u2013716. https:\/\/doi.org\/10.1007\/s11096-022-01397-5","journal-title":"Int J Clin Pharm"},{"key":"3954_CR18","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P (2023) Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. EClinicalMedicine 59:101967. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967","journal-title":"EClinicalMedicine"},{"issue":"3","key":"3954_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Giunchi V, Battini V, Puligheddu S, Khouri C, Carnovale C, Raschi E, Poluzzi E (2024) Enhancing transparency in defining studied drugs: the open-source living DiAna dictionary for standardizing drug names in the FAERS. Drug Saf 47(3):271\u2013284. https:\/\/doi.org\/10.1007\/s40264-023-01391-4","journal-title":"Drug Saf"},{"issue":"1","key":"3954_CR20","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-021-90108-7","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, Hu Q, Tian F, Wu F, Li Y, Xu T (2021) A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep 11(1):10709. https:\/\/doi.org\/10.1038\/s41598-021-90108-7","journal-title":"Sci Rep"},{"key":"3954_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Noren GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C (2024) The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"issue":"8","key":"3954_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"3954_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","volume":"27","author":"E Raschi","year":"2017","unstructured":"Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, Poluzzi E (2017) Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis 27(12):1098\u20131107. https:\/\/doi.org\/10.1016\/j.numecd.2017.10.008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"3954_CR24","unstructured":"FDA (2023) In: ed"},{"key":"3954_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fphar.2018.00197","volume":"9","author":"Y Noguchi","year":"2018","unstructured":"Noguchi Y, Ueno A, Otsubo M, Katsuno H, Sugita I, Kanematsu Y, Yoshida A, Esaki H, Tachi T, Teramachi H (2018) A new search method using association rule mining for drug-drug interaction based on spontaneous report system. Front Pharmacol 9:197. https:\/\/doi.org\/10.3389\/fphar.2018.00197","journal-title":"Front Pharmacol"},{"key":"3954_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3389\/fmicb.2019.00687","volume":"10","author":"CL Cazer","year":"2019","unstructured":"Cazer CL, Al-Mamun MA, Kaniyamattam K, Love WJ, Booth JG, Lanzas C, Grohn YT (2019) Shared multidrug resistance patterns in Chicken-Associated Escherichia coli identified by association rule mining. Front Microbiol 10:687. https:\/\/doi.org\/10.3389\/fmicb.2019.00687","journal-title":"Front Microbiol"},{"issue":"4","key":"3954_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","volume":"64","author":"BT Thakrar","year":"2007","unstructured":"Thakrar BT, Grundschober SB, Doessegger L (2007) Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64(4):489\u2013495. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02900.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3954_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3820\/jjpe.19.39","volume":"19","author":"Y Susuta","year":"2014","unstructured":"Susuta Y, Takahashi Y (2014) Safety risk evaluation methodology in detecting the medicine concomitant use risk which might cause critical drug rash. Japanese J Pharamacoepidemiology Japanese J Pharamacoepidemiology 19(1):39\u201349","journal-title":"Japanese J Pharamacoepidemiology Japanese J Pharamacoepidemiology"},{"key":"3954_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010004","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Aoyama K, Kubo S, Tachi T, Teramachi H (2020) Improved detection criteria for detecting drug-drug interaction signals using the proportional reporting ratio. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14010004","journal-title":"Pharmaceuticals (Basel)"},{"key":"3954_CR30","volume-title":"R: A Language and environment for statistical computing","author":"R Core Team","year":"2025","unstructured":"R Core Team (2025) R: A Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"issue":"8","key":"3954_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","volume":"48","author":"N Zaki","year":"2023","unstructured":"Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ (2023) Long-term safety and maintenance of response with Esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology 48(8):1225\u20131233. https:\/\/doi.org\/10.1038\/s41386-023-01577-5","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"3954_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","volume":"55","author":"F Franconi","year":"2007","unstructured":"Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007) Gender differences in drug responses. Pharmacol Res 55(2):81\u201395. https:\/\/doi.org\/10.1016\/j.phrs.2006.11.001","journal-title":"Pharmacol Res"},{"key":"3954_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030298","author":"AC Brabete","year":"2022","unstructured":"Brabete AC, Greaves L, Maximos M, Huber E, Li A, Le ML (2022) A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15030298","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"3954_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jagp.2021.09.014","volume":"30","author":"R Ochs-Ross","year":"2022","unstructured":"Ochs-Ross R, Wajs E, Daly EJ, Zhang Y, Lane R, Lim P, Drevets WC, Steffens DC, Sanacora G, Jamieson C, Hough D, Manji H, Singh JB (2022) Comparison of long-term efficacy and safety of Esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study. Am J Geriatr Psychiatry 30(5):541\u2013556. https:\/\/doi.org\/10.1016\/j.jagp.2021.09.014","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"3954_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00213-011-2623-7","volume":"222","author":"P Corbeil","year":"2012","unstructured":"Corbeil P, Rodrigue J, Simoneau M, Cohen H, Pourcher E (2012) Influence of risperidone on balance control in young healthy individuals. Psychopharmacology 222(1):59\u201369. https:\/\/doi.org\/10.1007\/s00213-011-2623-7","journal-title":"Psychopharmacology"},{"issue":"10","key":"3954_CR36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","volume":"24","author":"JKE Veraart","year":"2021","unstructured":"Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ (2021) Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. Int J Neuropsychopharmacol 24(10):808\u2013831. https:\/\/doi.org\/10.1093\/ijnp\/pyab039","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 1","key":"3954_CR37","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria C, Leporini C, Chimirri S, Marrazzo G, Sacchetta S, Bruno L, Lista RM, Staltari O, Scuteri A, Scicchitano F, Russo E (2013) Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two challenging case reports. J Pharmacol Pharmacother 4(Suppl 1):S66-72. https:\/\/doi.org\/10.4103\/0976-500X.120955","journal-title":"J Pharmacol Pharmacother"},{"issue":"12","key":"3954_CR38","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","volume":"70","author":"NS van De Ven","year":"2020","unstructured":"van De Ven NS, Pozniak AL, Levi JA, Clayden P, Garratt A, Redd C, Mofenson LM, Hill A (2020) Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy. Clin Infect Dis 70(12):2599\u20132606. https:\/\/doi.org\/10.1093\/cid\/ciz684","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.1007\/s00228-026-04007-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000}}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03954-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:58:17Z","timestamp":1771804697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03954-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3954"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03954-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00228-026-04007-9","URL":"https:\/\/doi.org\/10.1007\/s00228-026-04007-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the FAERS database is accessible to the public and patient records are anonymized and de-identified, approval from the Ethical Committee and informed consent are not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}